<DOC>
	<DOCNO>NCT02262715</DOCNO>
	<brief_summary>The purpose study investigate drug-drug interaction VX-787 oseltamivir , co-administered steady-state healthy participant . In addition safety , tolerability pharmacokinetics ( study way drug enters leave blood tissue time ) VX-787 assess .</brief_summary>
	<brief_title>A Study Assess Drug-Drug Interaction Between VX-787 Oseltamivir</brief_title>
	<detailed_description>This study consist 2 part . Part 1 open-label ( medical research study participant researcher tell treatment participant receive ) , randomize ( treatment group assign chance ) , 3-way crossover ( method use switch participant one treatment group another clinical trial ) study estimate drug-drug interaction VX-787 oseltamivir . It consist 3 phase : Screening phase , Treatment phase Follow-up phase . Treatment phase include 3 treatment session , participant receive Treatment A ( VX-787 , 600 milligram [ mg ] 2 time day Day 1 4 , follow single dose VX 787 , 600 mg Day 5 ) ; Treatment B ( Oseltamivir , 75 mg 2 time day Day 1 4 , follow single dose oseltamivir 75 mg Day 5 ) Treatment C ( VX-787 , 600 mg 2 time day + oseltamivir , 75 mg 2 time day Day 1 4 , follow single dose VX-787 , 600 mg + single dose oseltamivir , 75 mg Day 5 ) . Each treatment session separate wash-out period 5 day . The order participant receive treatment A , B C decide randomization . Part 2 double-blind ( medical research study neither researcher participant know treatment subject receive ) , randomize , placebo-controlled . It consist 3 phase : Screening phase , Treatment phase Follow-up phase . In Treatment phase participant randomly assign VX-787 , 600 mg placebo 2 time day , Day 1 9 , follow single dose VX-787 600 mg placebo morning Day 10 . Pharmacokinetic parameter assess primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Female participant must nonchildbearing potential : postmenopausal least 2 year ( amenorrheal least 3 year serum follicle stimulate hormone [ FSH ] level great [ &gt; ] 40 international unit per liter [ IU/L ] ) , surgically sterile ( total hysterectomy , bilateral oophorectomy , bilateral tubal ligation/bilateral tubal clip without reversal operation ) , otherwise incapable become pregnant Participants must nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior screen Participants must Body Mass Index ( BMI : weight kg divide square height meter ) 18.0 30.0 kilogram per meter square [ kg/m^2 ] Participants must willing/able adhere prohibition restriction specify protocol study procedures Participants must healthy basis medical evaluation reveals absence clinically significant abnormality include physical examination , medical history , vital sign result blood biochemistry , blood coagulation hematology test urinalysis perform screen Participants past history heart arrhythmia ( example , extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT Syndrome ) Participants history evidence use alcohol , barbiturate , amphetamine , recreational narcotic drug use within past 1 year , Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participants current hepatitis A infection ( confirm hepatitis A antibody immunoglobulin M [ IgM ] ) , hepatitis B infection ( confirm hepatitis B surface antigen [ HBsAg ] ) , hepatitis C infection ( confirm hepatitis C virus [ HCV ] antibody ) , human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection study screen Participants positive urine drug test alcohol breath test study screen . Urine test presence amphetamine , benzodiazepine , cocaine , cannabinoids , opioids , methadone barbiturates Participants know allergy , hypersensitivity , intolerance VX787 , oseltamivir , excipients drug product use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Oseltamivir</keyword>
	<keyword>VX-787</keyword>
</DOC>